Tagged with Netherlands

Pharma In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager Managed Equipment Services (MES) Europe, and Dick Blesing (DB), General Manager Netherlands, explain how Toshiba Medical System is becoming a true healthcare service provider, thanks to an innovative and…

Pharma DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to help overcome them. The Vice President and Commercial Director discuss how the services of the logistic provider are evolving to better adapt to the new needs of the industry and the business segments offering…

Pharma Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses the need for more transparency in the pharmaceutical industry and highlights the need for all stakeholders in the industry to…

Pharma After having successfully acquired its first dialysis center in the Netherlands, Fresenius Medical Care, the market leader for kidney failure products and services, is looking to develop more partnerships with other hospitals and dialysis centers to help Dutch patients benefit from their patient-centric expertise. CEO Ellen Gisjbers also advocates for…

Pharma Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens, as well as its perception of pay-for-performance models, pan-European joint-reimbursement initiatives, and Zorginstituut’s policies on orphan drugs reimbursement and quality…

Pharma DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB Schenker announced the company’s Vision 2020. Can you please elaborate on this vision? BC: This strategy is about being an eco-pioneer,…

Pharma Floris Van Haselen, Business Development Director Europe for O&M Movianto, one of the rare logistics companies to be fully specialized and to only operate in the healthcare sector, explains how the company wants to help its customers bring their products closer to the “Point of Care” thanks to its flexibility and expertise. With…

Pharma Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius Clinical aims to become the partner of choice for the pharmaceutical industry by strengthening clinical trial credibility, enhancing its quality…

Pharma Pharmaceuticals Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares her multi-country experience in market access and innovation perception. The Gedeon Richter Benelux affiliate only opened in 2012. What were…

Pharma Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has helped the company to become profitable and consider ambitious new objectives. Bilthoven Biologicals has a very unique history, having started…

Pharma Rob de Roock, Director CL Healthcare for UPS Europe, gives us a brief outline of the current market dynamics impacting the booming European healthcare logistics industry and explains how UPS offers the best way to transform client’s supply chain into a strong competitive advantage thanks to compliance expertise and tailored-made…

Pharma Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for a more comprehensive approach to the disease life cycle and for more transparency during market access procedures while the Dutch…